Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $407.90, demonstrating a -1.05% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily ...

Vertex Pharmaceuticals (VRTX) shares have been fairly steady recently, as investors digest the company’s financial ...

Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades ...

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Vertex Pharmaceuticals Incorporated VRTX stock has declined 23.6% in the past six months, mainly due to recent pipeline setbacks. In August 2025, Vertex’s phase II study on the oral formulation of ...

The company had to abandon the development of a medicine for type 1 diabetes (T1D), while another therapy in development for acute pain failed a phase 2 study. The biotech company also encountered ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best biotech stocks to buy. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) participated in the Bank of America Global Healthcare ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

For two decades, US biotech Vertex (Nasdaq: VRTX) built a reputation as one of the few companies to pair cutting-edge science ...